Form 4: TELA Bio Officer Granted RSUs, Tax Withholdings Follow

TELA Bio's Chief Accounting Officer, Megan Smeykal, received a grant of 32,850 restricted stock units, with subsequent share disposals for tax obligations.

Summary

• Megan Smeykal, Chief Accounting Officer of TELA Bio, Inc., was granted 32,850 restricted stock units (RSUs) on February 18, 2026.
• These RSUs will vest in four equal annual installments, commencing on February 18, 2027, contingent upon continuous service.
• Following the RSU grant, shares were withheld by the Issuer to satisfy applicable withholding taxes upon vesting of RSUs.
• Specifically, 795 shares were disposed of on February 19, 2026, at a price of $0.795 per share for tax purposes.
• An additional 1,590 shares were disposed of on February 21, 2026, at $0.7174 per share for tax purposes.
• A further 423 shares were disposed of on February 23, 2026, at $0.766 per share for tax purposes.
• After these transactions, Megan Smeykal beneficially owns 66,873 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The RSU grant is a standard compensation practice, and the share disposals are routine tax-related transactions, neither indicating significant positive nor negative operational or financial developments.

Positives

• The grant of 32,850 restricted stock units to the Chief Accounting Officer aligns management's long-term interests with those of shareholders, incentivizing sustained performance and value creation.

Negatives

• A total of 2,808 shares were disposed of across three separate transactions (February 19, 21, and 23, 2026) to cover tax withholding obligations, reducing the officer's direct beneficial ownership.

Future Outlook

The restricted stock units granted to the Chief Accounting Officer are scheduled to vest in four equal annual installments, beginning on February 18, 2027, subject to continuous service.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units (RSUs) is a common form of executive compensation in the biotechnology and medical device industries, designed to align executive incentives with long-term shareholder value. The subsequent share disposals for tax withholding are also a standard practice upon RSU vesting or grant, reflecting the tax implications of such equity awards.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Accounting Officer's financial interests with long-term shareholder value creation, potentially fostering greater commitment to company performance.
• Employees: The compensation structure for a key executive may serve as a benchmark or signal for broader employee incentive programs, though this filing specifically pertains to one officer.

Next Steps

• The restricted stock units will vest in four equal annual installments, with the first installment occurring on February 18, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and subsequent tax-related share disposals. It does not contain information that would fundamentally alter the company's valuation or strategic outlook. Therefore, a 'hold' recommendation is appropriate as there is no new material information to warrant a change in investment thesis.

Keywords

TELA Bio, Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Megan Smeykal, Chief Accounting Officer, Equity Grant